Shots:
- The US FDA has granted BTD to GSK5764227 (GSK’227) for treating r/r osteosarcoma in patients with disease progression on at least 2 prior lines of therapy
- Designation was supported by P-II (ARTEMIS-002) trial (carried out by Hansoh Pharma) assessing the safety & efficacy of GSK’227 to treat patients (n=60; 42 had osteosarcoma) with r/r osteosarcoma plus other unresectable bone & soft tissue sarcomas. Results were highlighted at ASCO 2024
- GSK’227 (HS-20093) is a B7-H3-targeted ADC developed by Hansoh Pharma for various solid tumors. In 2023, GSK acquired global rights (excl. China’s mainland, Hong Kong, Macau & Taiwan) for its development & launched a global P-I trial in Aug 2024
Ref: GSK | Image: GSK
Related News:- GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
